Catch up on the top radiology content of the past week.
News|Articles|August 20, 2025
Should Chest CT be Routine for Prostate Cancer Patients on Androgen Deprivation Therapy?
Author(s)Jeff Hall
Nine months after initiation of androgen deprivation therapy (ADT), prostate cancer patients with higher myocardial extracellular volume (ECV) — derived from chest contrast-enhanced CT — had over a fourfold higher risk for major adverse cardiovascular events (MACEs), according to new research.
Advertisement
Advertisement
For patients receiving androgen deprivation therapy (ADT) for prostate cancer (PCa), emerging research affirms that assessing myocardial extracellular volume (ECV) from chest contrast-enhanced computed tomography (CECT) may provide significant utility in monitoring for cardiotoxicity and predicting major adverse cardiovascular events (MACEs).
Related to this article
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
Catch up on the most-well viewed radiology content in September 2026.
Catch up on the most well-viewed video interviews from Diagnostic Imaging in September 2026.
Catch up on the top AI-related news and research in radiology over the past month.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
The BiPASS program, which combines 68Ga PSMA PET imaging with prostate MRI prior to the use of prostate biopsy, is slated to be evaluated in an impending phase 3 trial.
Advertisement
Advertisement